Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Esperion (NASDAQ: ESPR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Wednesday, January 15, 2025, at 3:45 p.m. PT. The presentation will be accessible via webcast through Esperion's investor and media section, with replay available for approximately 90 days.
Esperion is a commercial stage biopharmaceutical company that has developed the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. These medications are backed by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new structural and functional insights for developing highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference, in programma per mercoledì 15 gennaio 2025, alle 15:45 PT. La presentazione sarà accessibile tramite webcast nella sezione dedicata agli investitori e ai media di Esperion, con un replay disponibile per circa 90 giorni.
Esperion è un'azienda biofarmaceutica in fase commerciale che ha sviluppato l'unico farmaco orale approvato dalla FDA, da assumere una volta al giorno, non-statinico, per pazienti con LDL-C elevato e rischio di malattie cardiovascolari. Questi farmaci sono supportati dallo studio CLEAR sui risultati cardiovascolari, che ha coinvolto quasi 14.000 pazienti.
L'azienda sta avanzando con il suo programma di prossima generazione, concentrandosi sugli inibitori dell'ATP citrato liasi (ACLYi), sfruttando nuove intuizioni strutturali e funzionali per sviluppare inibitori altamente potenti e specifici con meccanismi alosterici. Esperion punta ad espandersi a livello globale attraverso l'esecuzione commerciale, partnership internazionali e il progresso del pipeline pre-clinico.
Esperion (NASDAQ: ESPR) ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare programada para el miércoles 15 de enero de 2025, a las 3:45 p.m. PT. La presentación será accesible a través de un webcast en la sección de inversores y medios de Esperion, con una repetición disponible por aproximadamente 90 días.
Esperion es una compañía biofarmacéutica en etapa comercial que ha desarrollado el único medicamento oral aprobado por la FDA, con una dosificación diaria, no estatínico, para pacientes con LDL-C elevado y riesgo de enfermedades cardiovasculares. Estos medicamentos están respaldados por el estudio CLEAR de resultados cardiovasculares, que involucró a casi 14,000 pacientes.
La empresa está avanzando en su programa de próxima generación que se centra en los inhibidores de la ATP citrato liasa (ACLYi), aprovechando nuevas percepciones estructurales y funcionales para desarrollar inhibidores altamente potentes y específicos con mecanismos alostéricos. Esperion tiene como objetivo expandirse a nivel global mediante la ejecución comercial, asociaciones internacionales y el avance de su pipeline preclínico.
Esperion (NASDAQ: ESPR)는 2025년 1월 15일 수요일 오후 3시 45분 PT에 예정된 제43회 연례 J.P. Morgan Healthcare Conference에 참여할 것이라고 발표했습니다. 발표는 Esperion의 투자자 및 미디어 섹션을 통해 웹캐스트로 접근 가능하며, 약 90일 동안 다시 볼 수 있습니다.
Esperion은 LDL-C 수치가 높고 심혈관 질환 위험이 있는 환자를 위해 FDA 승인을 받은 유일한 경구용, 하루 한 번 복용하는 비스타틴 약물을 개발한 상업 단계의 생물 제약 회사입니다. 이 약물들은 거의 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험에 의해 뒷받침됩니다.
회사는 ATP 시트레이트 라이아제 억제제(ACLYi)에 중점을 둔 차세대 프로그램을 진행 중이며, 높은 효능과 특정성을 가진 억제제를 개발하기 위해 새로운 구조적 및 기능적 통찰력을 활용하고 있습니다. Esperion은 상업적 실행, 국제 파트너십 및 전임상 파이프라인 진행을 통해 글로벌로 확장하는 것을 목표로 하고 있습니다.
Esperion (NASDAQ: ESPR) a annoncé sa participation à la 43e Conférence Annuelle de J.P. Morgan Healthcare, prévue pour le mercredi 15 janvier 2025, à 15h45 PT. La présentation sera accessible par webcast dans la section investisseurs et médias d'Esperion, avec une rediffusion disponible pendant environ 90 jours.
Esperion est une entreprise biopharmaceutique en phase commerciale qui a développé le seul médicament oral approuvé par la FDA, à prendre une fois par jour, non statinique, pour les patients ayant un LDL-C élevé et un risque de maladies cardiovasculaires. Ces médicaments sont soutenus par l'étude CLEAR sur les résultats cardiovasculaires, qui a impliqué près de 14 000 patients.
L'entreprise fait avancer son programme de prochaine génération axé sur les inhibiteurs de l'ATP citrate lyase (ACLYi), s'appuyant sur de nouvelles informations structurelles et fonctionnelles pour développer des inhibiteurs très puissants et spécifiques avec des mécanismes allostériques. Esperion vise à s'étendre à l'échelle mondiale grâce à l'exécution commerciale, des partenariats internationaux et des avancées dans le pipeline préclinique.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare angekündigt, die am Mittwoch, den 15. Januar 2025, um 15:45 Uhr PT stattfinden wird. Die Präsentation wird über ein Webcast in der Investoren- und Mediensektion von Esperion zugänglich sein, mit einer Wiederholung, die etwa 90 Tage verfügbar sein wird.
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das das einzige von der FDA zugelassene orale, einmal täglich einzunehmende nicht-statinische Medikament für Patienten mit erhöhtem LDL-C und Risiko für Herz-Kreislauf-Erkrankungen entwickelt hat. Diese Medikamente werden durch die CLEAR-Studie zu kardiovaskulären Ergebnissen unterstützt, an der fast 14.000 Patienten teilgenommen haben.
Das Unternehmen entwickelt ein Programm der nächsten Generation, das sich auf ATP-Citrat-Lyase-Inhibitoren (ACLYi) konzentriert, und nutzt neue strukturelle sowie funktionale Einblicke zur Entwicklung hochwirksamer und spezifischer Inhibitoren mit allosterischen Mechanismen. Esperion hat das Ziel, weltweit durch kommerzielle Umsetzung, internationale Partnerschaften und Fortschritte in der präklinischen Pipeline zu expandieren.
- None.
- None.
ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will Esperion's (ESPR) J.P. Morgan Conference webcast be available for replay?
What are the key therapeutic areas Esperion (ESPR) is focusing on in 2025?
How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?
What distinguishes Esperion's (ESPR) FDA-approved medications in the market?
